D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review. Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food ...

With California wildfires triggering a massive rebuilding process that could take several years, investors are looking closer at lumber stocks.

VHX-896 is under clinical development by Vanda Pharmaceuticals and currently in Phase III for Schizophrenia. According to GlobalData, Phase III drugs for Schizophrenia have a 68% phase transition ...

Tradipitant is under clinical development by Vanda Pharmaceuticals and currently in Phase III for Motion Sickness. According to GlobalData, Phase III drugs for Motion Sickness have a 100% phase ...

Also Read: Over 200% Stock Upside – Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst In September, the FDA issued a Complete Response Letter to the company.

After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has publicly laid out its reasoning for rejecting Vanda Pharmaceuticals’ ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

The FDA met resistance from a three-judge panel Wednesday over its decision to refuse approval of Vanda Pharmaceuticals Inc.’s jet lag disorder drug. At issue in arguments before the US Court of ...